Fujita Tomoko, Asagoe Kohsuke, Sakoda Hiroto
Department of Internal Medicine, Sumitomo Hospital.
Rinsho Ketsueki. 2003 Apr;44(4):249-53.
We report on a case of splenic lymphoma with villous lymphocytes (SLVL) which responded well to rituximab. A 50-year-old man was admitted because of splenomegaly. Abnormal lymphocytes of B cell lineage with moderately basophilic cytoplasm and unevenly distributed villi (villous cells) were found, both in the peripheral blood and bone marrow. CHOP and CHOP-E were performed, without any remarkable change in the size of the spleen. However, after infusion of rituximab (375 mg/m2, once weekly for 2 weeks), there was a marked reduction of the spleen size and the number of circulating villous cells. Splenectomy was performed afterwards, followed by 2 cycles of rituximab infusion. The patient is now followed on an outpatient basis without any sign of relapse.
我们报告一例对利妥昔单抗反应良好的脾绒毛状淋巴细胞淋巴瘤(SLVL)。一名50岁男性因脾肿大入院。在外周血和骨髓中均发现了具有中度嗜碱性细胞质和绒毛分布不均(绒毛状细胞)的B细胞系异常淋巴细胞。进行了CHOP和CHOP-E方案化疗,脾脏大小无明显变化。然而,在输注利妥昔单抗(375mg/m²,每周一次,共2周)后,脾脏大小和循环绒毛状细胞数量明显减少。随后进行了脾切除术,接着又进行了2个周期的利妥昔单抗输注。该患者目前在门诊随访,无任何复发迹象。